EUVIMEDEUVIMED entdecken
Crossref

Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation

Mingli Wei, Chenxiao Chu, Huaiwei Ding, Jiansong Zhao, Muse Ji, Xinxin Liang, Xiaoshuang Bi, Jiaqi Zhao, Jingxin Gou, Tian Yin, Haibing He iD, Xing Tang iD und 2 weitere

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.6c00317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Mingli Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang110016, Liaoning, China. Hauptthemen laut MEDLINE: Prodrugs, Nanoparticles, Lipoproteins, LDL, Taxoids. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Basic Research Program of China (973 Program), National Natural Science Foundation of China (NSFC), Frontier Technology Platform Program of Educational Department of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cabazitaxel (CTX) exhibits potent antineoplastic activity and is demonstrated to promote antitumor immunity by triggering immunogenic cell death (ICD). This is commonly used in the clinical treatment of advanced and metastatic triple-negative breast cancer (TNBC). However, the therapeutic index of commercial CTX injections is severely restricted by their definite systemic toxicity and low tolerability. Herein, we developed biomimetic low-density lipoprotein nanoparticles (CTX2TK&VP@LDL NPs) by integrating ROS-responsive CTX dimeric prodrugs (CTX2TK) and the photosensitizer verteporfin (VP) into LDL NPs to selectively target tumors and achieve synergistic chemophotodynamic therapy and immunotherapy for TNBC with improved biosafety. CTX2TK&VP@LDL NPs were able to enhance the accumulation and cellular uptake in 4T1 tumors overexpressing LDL receptor, improving the targeted codelivery efficiency. When CTX2TK&VP@LDL NPs were deposited at the tumor sites, localized 1O2 was generated upon irradiation for triggering ultrafast CTX release with low premature CTX leakage in the off-target tissue. Additionally, the generated 1O2 can further synergistically reinforce ICD and elicit robust antitumor immune activation. The combination treatment with CTX2TK&VP@LDL NPs and PD-L1 blockade notably inhibited abscopal tumor growth and lung metastasis. Taken together, the biomimetic CTX2TK&VP@LDL NPs exploit endogenous LDL functionality to enable receptor-mediated tumor targeting and synergistic chemophotodynamic immune activation, providing an effective and safe therapeutic strategy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNanoparticlesLipoproteins, LDLTaxoidsVerteporfinTriple Negative Breast NeoplasmsAnimalsFemaleMiceCell Line, TumorHumansMice, Inbred BALB CPhotosensitizing AgentsAntineoplastic Agents

Stichwörter der Autor:innen

enhanced immunogenic cell deathlight-activated prodrugslow-density lipoproteinminimal toxicitymultimodal combination therapy

Substanzen

ProdrugsLipoproteins, LDLTaxoidsVerteporfincabazitaxelPhotosensitizing AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang110016, Liaoning, China.
  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang110016, China.
  • School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, Liaoning, China.
  • College of Science, Shenyang University, Shenyang110044, China.

ORCID-Profile: Haibing He, Xing Tang, Yu Zhang

Förderung

  • National Basic Research Program of China (973 Program)
  • National Natural Science Foundation of China (NSFC)
  • Frontier Technology Platform Program of Educational Department of Liaoning Province

Zitieren

APA

Wei, M., Chu, C., Ding, H., Zhao, J., Ji, M., Liang, X., Bi, X., Zhao, J., Gou, J., Yin, T., He, H., Tang, X., Zhang, Y., & Zhang, Y. (2026). Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00317

Vancouver

Wei M, Chu C, Ding H, Zhao J, Ji M, Liang X, et al. Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00317

BibTeX
@article{Wei2026,
  author = {Wei, Mingli and Chu, Chenxiao and Ding, Huaiwei and Zhao, Jiansong and Ji, Muse and Liang, Xinxin and Bi, Xiaoshuang and Zhao, Jiaqi and Gou, Jingxin and Yin, Tian and He, Haibing and Tang, Xing and Zhang, Yan and Zhang, Yu},
  title = {Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00317}
}
Kostenlos starten →